Search results
Results from the WOW.Com Content Network
This is the list of Schedule I controlled substances in the United States as defined by the Controlled Substances Act. [1] The following findings are required for substances to be placed in this schedule: [2]
The Senate Judiciary Committee is holding a hearing Tuesday morning to consider legislation that would permanently classify fentanyl-related substances as a Schedule 1 drug under the Controlled ...
The Schedule 1 list is one of three lists. Chemicals which are feasible to use as weapons, and their precursors, but which have legitimate applications as well are listed in Schedule 2 (small-scale applications) and Schedule 3 (large-scale applications). The use of Schedule 1, 2, or 3 chemicals as weapons is banned by the Convention.
Schedule V; The drug or other substance has a low potential for abuse relative to the drugs or other substances in schedule IV; The drug or other substance has a currently accepted medical use in treatment in the United States; Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to ...
Supporters of the classification, including some lawmakers and law enforcement officials, suggest that permanently making the drug a Schedule 1 drug would help strengthen the government's ability ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Special pages; Help; Learn to edit; Community portal; Recent changes; Upload file
[4] [1] [5] DOM was first synthesized by Alexander Shulgin, and later described in his book PiHKAL: A Chemical Love Story (1991). [1] It is classified as a Schedule I controlled substance in the United States, and is similarly controlled in other parts of the world. [1] Internationally, it is a Schedule I drug under the Convention on ...
Starting in 2023, it has become an increasingly widespread drug of abuse in its own right, linked to numerous overdose cases, and may be considered an analog of the schedule 1 drug metonitazene. In October 2023, the DEA published an intent to temporarily schedule etonitazepipne and N-desethylisotonitazene.